Adaptive Biotechnologies (NASDAQ:ADPT) Posts Earnings Results, Misses Expectations By $0.12 EPS

Adaptive Biotechnologies (NASDAQ:ADPT) announced its quarterly earnings results on Wednesday. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.12), FiscalAI reports. The company had revenue of $71.55 million for the quarter, compared to the consensus estimate of $65.44 million. Adaptive Biotechnologies had a negative net margin of 16.82% and a negative return on equity of 40.06%.

Here are the key takeaways from Adaptive Biotechnologies’ conference call:

• MRD delivered strong growth and improved profitability: Core MRD revenue rose 49% year over year excluding prior-year milestones, while sequencing gross margin expanded to 72% and MRD adjusted EBITDA increased to $9.1 million.
• Clinical testing momentum remained broad-based. clonoSEQ volume grew 43% year over year, with blood-based testing up 68%, community testing up 65%, and nearly 5,200 ordering clinicians; multiple myeloma volume rose 15% sequentially.
• Adaptive raised full-year MRD revenue guidance to $268 million-$278 million from $260 million-$270 million and remains on track for positive company-wide adjusted EBITDA and free cash flow by year-end 2026.
• The company is pursuing a separation of its Immune Medicine business, with Morgan Stanley advising on strategic alternatives and a preferred path expected by year-end; Adaptive is winding down its research-use-only pharma services business to focus on proprietary immune data, AI models, and autoimmune target discovery.
• Adaptive strengthened its balance sheet with a $340 million zero-coupon convertible note offering, using proceeds to retire the OrbiMed agreement, reduce potential dilution through a capped-call and share repurchase, and support MRD investment and the separation strategy.

Adaptive Biotechnologies Price Performance

Shares of Adaptive Biotechnologies stock traded up $0.04 during trading on Wednesday, hitting $22.56. The company’s stock had a trading volume of 3,146,817 shares, compared to its average volume of 2,314,238. The stock has a market cap of $3.61 billion, a price-to-earnings ratio of -68.36 and a beta of 2.07. Adaptive Biotechnologies has a 52 week low of $9.96 and a 52 week high of $23.15. The stock has a 50-day moving average price of $18.88 and a two-hundred day moving average price of $16.51.

Key Headlines Impacting Adaptive Biotechnologies

Here are the key news stories impacting Adaptive Biotechnologies this week:

• Positive Sentiment: Second-quarter revenue reached $71.55 million, exceeding analysts’ $65.44 million consensus estimate. The result suggests continued demand for Adaptive’s immune-receptor sequencing and clinical products. Adaptive Biotechnologies Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Brokerage coverage remains broadly supportive, with five Buy ratings, one Hold and one Sell, producing a consensus “Moderate Buy” rating. Recent firms including BTIG Research and Guggenheim maintained Buy ratings, although their targets are close to current trading levels. Adaptive Biotechnologies Receives Moderate Buy Rating
• Neutral Sentiment: ADPT shares remain well above their 50-day and 200-day moving averages and close to the $23.15 52-week high, indicating strong momentum but also leaving the stock vulnerable to profit-taking if results or guidance disappoint.
• Negative Sentiment: Adaptive reported a quarterly loss of $0.25 per share, missing the $0.13 loss expected by analysts. The company continues to post negative profitability metrics, including a net margin of -16.82% and return on equity of -40.06%. Adaptive Biotechnologies Earnings Report
• Negative Sentiment: Insider Harlan Robins sold 492,400 shares worth approximately $10.8 million, reducing his direct ownership by 37.75%. The sale was made under a pre-arranged Rule 10b5-1 plan, which reduces its signaling value, but the transaction may still concern investors. Insider Selling at Adaptive Biotechnologies

Analysts Set New Price Targets

ADPT has been the subject of several research reports. Guggenheim increased their price objective on shares of Adaptive Biotechnologies from $21.00 to $22.00 and gave the company a “buy” rating in a research note on Monday, June 29th. Morgan Stanley boosted their target price on shares of Adaptive Biotechnologies from $18.00 to $20.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 9th. BTIG Research reiterated a “buy” rating and set a $22.00 price target on shares of Adaptive Biotechnologies in a report on Wednesday, June 17th. JPMorgan Chase & Co. dropped their price target on Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating for the company in a research note on Wednesday, May 6th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Adaptive Biotechnologies in a report on Friday, July 17th. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Adaptive Biotechnologies currently has a consensus rating of “Moderate Buy” and a consensus target price of $20.83.

Insider Buying and Selling

In other news, insider Sharon Benzeno sold 154,768 shares of the stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $21.14, for a total value of $3,271,795.52. Following the completion of the sale, the insider owned 221,278 shares of the company’s stock, valued at approximately $4,677,816.92. This represents a 41.16% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Harlan S. Robins sold 492,400 shares of the firm’s stock in a transaction dated Tuesday, July 21st. The stock was sold at an average price of $21.89, for a total value of $10,778,636.00. Following the transaction, the insider owned 812,058 shares of the company’s stock, valued at $17,775,949.62. This trade represents a 37.75% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 1,305,787 shares of company stock valued at $27,828,563 in the last quarter. 5.70% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Adaptive Biotechnologies

Hedge funds and other institutional investors have recently bought and sold shares of the company. Ameriprise Financial Inc. grew its holdings in Adaptive Biotechnologies by 84.3% during the 3rd quarter. Ameriprise Financial Inc. now owns 5,971,706 shares of the company’s stock worth $89,337,000 after acquiring an additional 2,731,648 shares during the period. Price T Rowe Associates Inc. MD raised its position in shares of Adaptive Biotechnologies by 303.4% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,387,361 shares of the company’s stock worth $71,252,000 after acquiring an additional 3,299,635 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of Adaptive Biotechnologies by 3.3% in the 4th quarter. Geode Capital Management LLC now owns 3,511,855 shares of the company’s stock valued at $57,041,000 after purchasing an additional 110,825 shares during the period. State Street Corp lifted its stake in shares of Adaptive Biotechnologies by 3.3% in the 4th quarter. State Street Corp now owns 3,181,644 shares of the company’s stock valued at $51,670,000 after purchasing an additional 102,362 shares during the period. Finally, Invesco Ltd. boosted its position in shares of Adaptive Biotechnologies by 248.8% during the 4th quarter. Invesco Ltd. now owns 3,107,653 shares of the company’s stock valued at $50,468,000 after purchasing an additional 2,216,595 shares in the last quarter. Institutional investors and hedge funds own 99.17% of the company’s stock.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.